Report of Foreign Issuer (6-k)
November 21 2018 - 4:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2018 (Report
Number 2)
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant’s name
into English)
PO Box 318, Tel-Aviv, Israel 6100201
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
¨
Attached
hereto and incorporated by reference herein is the Registrant
’
s Notice of Meeting for
the Annual and Extraordinary General Meeting of Shareholders to be held on December 26, 2018, or the Meeting.
Only shareholders of record
who hold Ordinary Shares, nominal value NIS 0.05, of the Registrant at the close of trading on the Nasdaq Capital Market on November
26, 2018, will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.
The
Notice of Meeting attached to this Form 6-K of the Registrant is incorporated by reference into the registration statements on
Form S-8 (File No. 333-203114 and File No. 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to
be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
Exhibit No.
|
99.1
|
Notice
of Meeting for the Annual and Extraordinary General Meeting of Shareholders to be held on December 26, 2018.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Bioblast Pharma Ltd.
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Dr. Dalia Megiddo
|
|
Name:
|
Dr. Dalia Megiddo
Chief Executive Officer
|
Date: November 21, 2018
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Apr 2023 to Apr 2024